Wall Street Outlook For Elevance Health, Inc. (ELV) Supported By Prior TD Cowen Upgrade

Elevance Health, Inc. (NYSE:ELV) is among the cheap healthcare stocks to bargain heading into 2026. As of December 7, Elevance Health, Inc. (NYSE:ELV) has a ‘Buy’ oregon equivalent standing from somewhat much than fractional of the analysts covering the stock. With a median terms people of $394, the banal has an upside imaginable of 19.12%.

On November 26, TD Cowen accrued the terms people connected Elevance Health, Inc. (NYSE:ELV) to $400.00 from $380.00, with an unchanged ‘Buy’ standing connected the stock, naming it arsenic its “Best Idea for 2026.” The steadfast raised concerns regarding managed care, describing it arsenic a “complicated concern landscape.” TD Cowen noted that the company’s existent 2026 EPS statement estimation is due and supports growth, with the steadfast expanding its 2026 EPS estimation to $27.25.

Dragon Images/Shutterstock.com

Earlier connected November 4, Mizuho trimmed its terms people connected Elevance Health, Inc. (NYSE:ELV) to $400 from $420, portion keeping an ‘Outperform’ standing connected the stock. The steadfast besides reduced 2026 and 2027 net guidance to amended bespeak added challenges successful Carelon.

Elevance Health, Inc. (NYSE:ELV) is an Indiana-based wellness benefits institution operating done 4 segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. Founded successful 2001, the institution is dedicated to simplifying the healthcare system.

While we admit the imaginable of ELV arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.